Concepts (92)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Kaplan-Meier Estimate | 2 | 2024 | 422 | 0.950 |
Why?
|
| Carcinoma, Neuroendocrine | 1 | 2023 | 11 | 0.810 |
Why?
|
| Neuroendocrine Tumors | 1 | 2023 | 22 | 0.800 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2021 | 525 | 0.660 |
Why?
|
| Immunotherapy | 2 | 2019 | 255 | 0.660 |
Why?
|
| Gene Expression Profiling | 2 | 2019 | 770 | 0.610 |
Why?
|
| Kynurenine | 1 | 2018 | 7 | 0.600 |
Why?
|
| Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2018 | 7 | 0.600 |
Why?
|
| Receptors, Aryl Hydrocarbon | 1 | 2018 | 15 | 0.590 |
Why?
|
| Tryptophan | 1 | 2018 | 57 | 0.590 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2019 | 103 | 0.580 |
Why?
|
| Kidney Neoplasms | 1 | 2019 | 160 | 0.560 |
Why?
|
| Formative Feedback | 1 | 2017 | 8 | 0.550 |
Why?
|
| Melanoma | 4 | 2021 | 331 | 0.500 |
Why?
|
| Schools | 1 | 2017 | 166 | 0.500 |
Why?
|
| Body Mass Index | 1 | 2019 | 867 | 0.480 |
Why?
|
| Students | 1 | 2017 | 217 | 0.470 |
Why?
|
| General Surgery | 1 | 2017 | 211 | 0.440 |
Why?
|
| Uveal Neoplasms | 2 | 2021 | 50 | 0.330 |
Why?
|
| Signal Transduction | 2 | 2023 | 3035 | 0.320 |
Why?
|
| Neoplasms | 1 | 2018 | 1364 | 0.280 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2021 | 448 | 0.260 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2023 | 309 | 0.220 |
Why?
|
| Mitotane | 1 | 2024 | 1 | 0.220 |
Why?
|
| Prostatic Neoplasms, Castration-Resistant | 1 | 2023 | 16 | 0.200 |
Why?
|
| Humans | 13 | 2024 | 63445 | 0.190 |
Why?
|
| Ipilimumab | 1 | 2021 | 8 | 0.180 |
Why?
|
| Prostatic Neoplasms | 1 | 2023 | 418 | 0.160 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2019 | 52 | 0.160 |
Why?
|
| Databases, Genetic | 1 | 2019 | 89 | 0.150 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2021 | 238 | 0.150 |
Why?
|
| Neovascularization, Pathologic | 1 | 2019 | 140 | 0.150 |
Why?
|
| Cell Line, Tumor | 2 | 2023 | 1469 | 0.150 |
Why?
|
| Immunomodulation | 1 | 2018 | 30 | 0.150 |
Why?
|
| Biomarkers, Tumor | 2 | 2019 | 507 | 0.140 |
Why?
|
| Adolescent | 2 | 2019 | 6245 | 0.140 |
Why?
|
| Aminolevulinic Acid | 1 | 2017 | 1 | 0.130 |
Why?
|
| Protoporphyrins | 1 | 2017 | 3 | 0.130 |
Why?
|
| Keratosis, Actinic | 1 | 2017 | 4 | 0.130 |
Why?
|
| Photosensitizing Agents | 1 | 2017 | 17 | 0.130 |
Why?
|
| California | 1 | 2017 | 174 | 0.130 |
Why?
|
| Photochemotherapy | 1 | 2017 | 24 | 0.130 |
Why?
|
| Organizational Innovation | 1 | 2017 | 82 | 0.130 |
Why?
|
| Enzyme Inhibitors | 1 | 2018 | 373 | 0.130 |
Why?
|
| Computational Biology | 1 | 2018 | 356 | 0.130 |
Why?
|
| Program Development | 1 | 2017 | 207 | 0.120 |
Why?
|
| Career Choice | 1 | 2017 | 132 | 0.120 |
Why?
|
| Skin Neoplasms | 1 | 2021 | 412 | 0.120 |
Why?
|
| Aged, 80 and over | 3 | 2021 | 5462 | 0.120 |
Why?
|
| Male | 7 | 2023 | 29891 | 0.120 |
Why?
|
| Disease Progression | 1 | 2019 | 1172 | 0.120 |
Why?
|
| Transcriptome | 1 | 2018 | 387 | 0.120 |
Why?
|
| Program Evaluation | 1 | 2017 | 487 | 0.110 |
Why?
|
| T-Lymphocytes | 1 | 2019 | 1007 | 0.110 |
Why?
|
| Androgen Antagonists | 2 | 2023 | 25 | 0.100 |
Why?
|
| Prognosis | 1 | 2018 | 1748 | 0.100 |
Why?
|
| Models, Biological | 1 | 2018 | 1180 | 0.100 |
Why?
|
| Curriculum | 1 | 2017 | 599 | 0.100 |
Why?
|
| PTEN Phosphohydrolase | 2 | 2023 | 84 | 0.100 |
Why?
|
| Phosphatidylinositol 3-Kinases | 2 | 2023 | 171 | 0.100 |
Why?
|
| Treatment Outcome | 2 | 2019 | 5680 | 0.090 |
Why?
|
| Proteomics | 2 | 2023 | 283 | 0.090 |
Why?
|
| Cohort Studies | 1 | 2017 | 2570 | 0.090 |
Why?
|
| Mutation | 1 | 2019 | 2612 | 0.090 |
Why?
|
| Female | 4 | 2021 | 32880 | 0.080 |
Why?
|
| Middle Aged | 4 | 2021 | 17613 | 0.080 |
Why?
|
| Aged | 3 | 2021 | 14447 | 0.080 |
Why?
|
| Neoplasm Metastasis | 2 | 2021 | 200 | 0.080 |
Why?
|
| Young Adult | 1 | 2019 | 4694 | 0.080 |
Why?
|
| Adult | 3 | 2021 | 16824 | 0.070 |
Why?
|
| Macrophages | 2 | 2023 | 1039 | 0.070 |
Why?
|
| Retrospective Studies | 1 | 2017 | 6658 | 0.060 |
Why?
|
| Lactates | 1 | 2023 | 29 | 0.050 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2023 | 57 | 0.050 |
Why?
|
| Lead | 1 | 2023 | 43 | 0.050 |
Why?
|
| beta Catenin | 1 | 2023 | 96 | 0.050 |
Why?
|
| Lactic Acid | 1 | 2023 | 76 | 0.050 |
Why?
|
| Wnt Signaling Pathway | 1 | 2023 | 81 | 0.050 |
Why?
|
| Phagocytosis | 1 | 2023 | 264 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2023 | 207 | 0.050 |
Why?
|
| Anilides | 1 | 2019 | 18 | 0.040 |
Why?
|
| Dacarbazine | 1 | 2019 | 18 | 0.040 |
Why?
|
| Mice | 2 | 2023 | 10844 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2021 | 583 | 0.040 |
Why?
|
| Transfection | 1 | 2021 | 694 | 0.040 |
Why?
|
| Pyridines | 1 | 2019 | 112 | 0.040 |
Why?
|
| Sunlight | 1 | 2017 | 30 | 0.030 |
Why?
|
| Face | 1 | 2017 | 36 | 0.030 |
Why?
|
| Scalp | 1 | 2017 | 29 | 0.030 |
Why?
|
| Animals | 2 | 2023 | 20663 | 0.030 |
Why?
|
| Pain | 1 | 2017 | 406 | 0.030 |
Why?
|
| Time Factors | 1 | 2017 | 3768 | 0.020 |
Why?
|